IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Core Viewpoint - The American Society of Breast Surgeons (ASBrS) is in the final stages of updating its guidelines to include cryoablation as a treatment option for low-risk breast cancer, which is expected to enhance the adoption of this minimally invasive procedure in the U.S. [1] Group 1: ASBrS Guidelines Update - The updated guidelines will recommend cryoablation for patients aged 70 years with low-risk tumors measuring 1.5 cm, treated with adjuvant endocrine therapy, including those unsuitable for surgery [1] - The proposed guidelines align with the FDA's marketing authorization for cryoablation granted in October 2025 [1] - The guidelines also suggest cryoablation for small benign tumors, such as fibroadenomas [1] Group 2: Clinical Evidence and Efficacy - The ICE3 trial, the largest study of its kind in the U.S., showed that only 3.1% of patients treated with cryoablation and endocrine therapy experienced local recurrence within 5 years, indicating efficacy comparable to lumpectomy [1] - The proposed updates reflect a growing body of clinical evidence supporting breast cryoablation, including peer-reviewed publications [1] Group 3: Market Implications - The inclusion of cryoablation in medical society guidelines is anticipated to lead to increased recommendations from breast surgeons, improving patient outcomes and accelerating commercial adoption [1] - IceCure's U.S. commercial team has noted growing interest in the ProSense® system, with installations at new locations across North America [1] - The U.S. breast cryoablation patient population is estimated at approximately 200,000 women annually, including 46,400 early-stage, low-risk patients aged 70 and over [1] Group 4: ProSense® System Overview - ProSense® is the first and only FDA-authorized device for the local treatment of low-risk breast cancer in women aged 70 and above, including those not suitable for surgical options [1] - The system utilizes liquid nitrogen to create large lethal zones for effective tumor destruction, enhancing patient recovery and reducing complications [1] - ProSense® is designed for fast, convenient office-based procedures, expanding treatment options for breast tumors [1]